Headquartered in Westlake Village, CA Fiscal year ends December NASDAQ: TTRX turntherapeutics.com
Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized (non-systemic) therapies for inflammatory and infectious skin diseases. The company's lead investigational candidate, GX-03, is a topical treatment being developed for atopic dermatitis, designed to deliver biologic-level efficacy without injectable administration or systemic immunosuppression. GX-03 targets the IL-36 inflammatory pathway and also demonstrates antimicrobial activity. The company is currently conducting a Phase 2 clinical trial in atopic dermatitis and is planning expansion into hidradenitis suppurativa. Turn Therapeutics is a pre-revenue company listed on Nasdaq under the ticker TTRX. Updated
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower…
Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized (non-systemic) therapies for inflammatory and infectious skin diseases.
The Wall Street consensus 12-month price target for TTRX is $25.00.
